Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 5/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | VEGFA | P15692 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808072 | 0.93 | CYP3A4 (0.73) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B | |
| SCHEMBL4808573 | 0.93 | CYP3A4 (0.84) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B | |
| SCHEMBL14262139 | 0.92 | CYP3A4 (1.00) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B | |
| SCHEMBL4801545 | 0.91 | CYP3A4 (0.82) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B | |
| SCHEMBL5322461 | 0.90 | CYP3A4 (0.80) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B | |
| SCHEMBL3665191 | 0.88 | CYP3A4 (0.67) | CYP3A4KCNH2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4800446 | 0.87 | CYP3A4 (0.76) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B | |
| SCHEMBL3664979 | 0.87 | CYP3A4 (0.70) | CYP3A4KCNH2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4581837 | 0.84 | CYP3A4 (0.69) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B | |
| SCHEMBL12849042 | 0.84 | CYP3A4 (0.69) | CYP3A4KCNH2CYP2C9CYP2C19MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | DUNN JAMES P | 2007-08-02 | — | — | US | disclosed |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | DUNN JAMES P | 2007-08-02 | — | — | US | disclosed |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | DUNN JAMES P | 2007-08-02 | — | — | US | disclosed |
| US-7208509-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208509-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | RRM2, RRM2B, SAMHD1 | CYP3A4 438/4885KCNH2 3216/4885CYP2C9 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.